01What Stem Cell Therapy for Systemic Lupus Is
Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks healthy tissue, potentially affecting the skin, joints, kidneys, blood cells, brain, heart, and lungs. It follows an unpredictable course of flares and remissions and varies widely in severity between patients.
Standard treatment includes corticosteroids, antimalarials (like hydroxychloroquine), immunosuppressants, and increasingly, targeted biologic therapies. Despite these options, a subset of patients have disease that remains difficult to control — this is the group most studied in MSC trials.
Do You Know about Lupus?
MSCs are of particular research interest in lupus because of their immunomodulatory properties — their ability to calm an overactive immune system rather than simply suppress it broadly, as many current lupus medications do. This is why lupus has attracted more rigorous MSC trial activity than many other autoimmune conditions.
02Symptoms of Systemic Lupus
Lupus symptoms vary enormously between patients and can affect multiple organ systems:
- Joint pain and swelling
- Skin rashes, including the characteristic “butterfly” facial rash
- Fatigue and low-grade fever
- Kidney involvement (lupus nephritis), which can be serious
- Chest pain from inflammation around the heart or lungs
- Sensitivity to sunlight
03Causes of Systemic Lupus
The exact cause of lupus is unknown, but several factors are believed to contribute:
- Genetic Predisposition: Family history increases risk, and certain genes are linked to lupus susceptibility.
- Hormonal Factors: Lupus is far more common in women, particularly during reproductive years, suggesting a hormonal role.
- Environmental Triggers: Sunlight, certain infections, and some medications can trigger flares in genetically susceptible individuals.
- Immune Dysregulation: The core problem is a malfunctioning immune system that fails to distinguish the body's own tissue from foreign invaders.
04How Systemic Lupus Is Diagnosed
Lupus diagnosis relies on a combination of clinical criteria, blood work, and sometimes biopsy:
- ANA (Antinuclear Antibody) Test: A key screening test; most lupus patients test positive, though a positive result alone doesn't confirm lupus.
- Additional Autoantibody Tests: Anti-dsDNA and anti-Sm antibodies are more specific for lupus.
- Complement Levels: Low C3/C4 complement levels often correlate with disease activity.
- Kidney Function Tests and Urinalysis: Used to screen for lupus nephritis.
- Classification Criteria: Rheumatologists use formal criteria (ACR/EULAR) combining clinical and laboratory findings for diagnosis.
05How Stem Cell Therapy Is Approached as a Treatment for Systemic Lupus
Current Standard of Care
Standard treatment is tailored to disease severity and organ involvement, and typically includes hydroxychloroquine as a foundation, corticosteroids for flares, immunosuppressants (such as mycophenolate or azathioprine) for more severe disease, and biologic therapies (such as belimumab or anifrolumab) for refractory cases.
Where Stem Cell Research Fits In
For patients whose lupus remains active despite standard immunosuppressive therapy, MSC infusion has been studied in academic Phase I/II trials as an add-on approach. The rationale is that MSCs can modulate immune cell behavior (including T-cells and B-cells implicated in lupus) rather than broadly suppressing the immune system.
06How It's Being Explored for Systemic Lupus
A Phase II randomized, double-blind, placebo-controlled trial (“MiSLE,” NCT02633163) conducted at the Medical University of South Carolina evaluated low- and high-dose allogeneic MSC infusion in patients with refractory lupus.
An earlier Phase I safety trial at the same institution (NCT03171194) established preliminary safety data for allogeneic MSC infusion in SLE patients.
A broader systematic review and meta-analysis of randomized controlled trials evaluating MSC therapy across several autoimmune diseases, including SLE, ankylosing spondylitis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, found encouraging but still-developing efficacy and safety signals across these conditions.
Separately, a randomized, double-blind, placebo-controlled trial of allogeneic umbilical cord-derived MSCs specifically for lupus nephritis (kidney involvement) has also been published in a peer-reviewed rheumatology journal.
07What the Systemic Lupus Treatment Process Looks Like
Day 1
- Pick-up from the airport to the hospital
- Initial consultation between doctor and patient to address any questions
- Admission formalities
- Clinical examination and lab tests as prescribed by the doctor
- Supportive therapy
Day 2
- Stem cell procedure
- Supportive therapies
- Physiotherapy, as appropriate
Day 3
- Supportive therapy
- Discharge formalities
- Drop-off at the airport
Note: For admission, patients should carry valid identification (passport, PAN card, or driving license) along with hard copies of relevant medical records and prior test results.
08Delivery Techniques Used in Stem Cell Therapy for Systemic Lupus
Depending on the treatment plan, stem cells may be administered using one or more of the following methods:
- Intravenous infusion (the method used in published clinical trials)
09Is Stem Cell Therapy Safe for Systemic Lupus?
Stem cell therapy for Systemic Lupus is discussed only after an individual medical evaluation, and safety depends heavily on that case-by-case review rather than on the therapy in general. As with any medical intervention, mild and temporary reactions (such as soreness or fatigue at the injection or infusion site) are possible, and a full risk discussion happens as part of your evaluation. It is not offered to patients in an acute or unstable phase of Systemic Lupus, and it is never positioned as a substitute for guideline-based care from your treating specialist. For a fuller picture of how safety, accreditation, and quality standards are handled, see our Safety and Guarantees page.
10Who Might Consider a Systemic Lupus Discussion — and Who Should Not
May be reasonable to discuss
- A confirmed systemic lupus diagnosis, with the patient medically stable and not in an acute emergency
- Prior imaging, neurology, and treatment records available for review
- The injury is past its acute phase, with the patient in a stable, chronic-care stage
- Realistic expectations that any benefit would be supportive and investigational, not a cure
- Willingness to continue rehabilitation and follow-up care alongside this discussion
Generally not appropriate
- Acute or unstable neurological emergencies requiring immediate critical care
- Active untreated infection, uncontrolled bleeding disorder, or advanced organ failure
- An active, untreated malignancy that has not been cleared by an oncologist
- Pregnancy, or an expectation that the therapy will reverse or cure the underlying condition
- Unwillingness to share prior medical records or to be evaluated before proceeding
This list is general and educational — it is not a substitute for an individual medical evaluation of your case.
11What a Systemic Lupus Supportive-Care Discussion Involves
A supportive-care discussion for Systemic Lupus isn't a single conversation — it follows a defined sequence, so nothing is recommended before your specific case has been reviewed. In broad terms:
- Record review: Your existing diagnosis, imaging, lab work, and treatment history for Systemic Lupus are reviewed by the medical team first.
- Case-by-case medical evaluation: A physician assesses whether any further discussion is medically reasonable for your specific case — many enquiries end here with a clear "not appropriate" answer, which is a valid and expected outcome.
- Coordination with your specialist: Where a discussion proceeds, it is coordinated so it does not conflict with your ongoing care from your treating specialist.
- Transparent, written explanation: Any recommendation is explained in plain language, including its investigational status, realistic expectations, and that no outcome is guaranteed.
- Ongoing standard care continues: At every stage, your prescribed treatment for Systemic Lupus continues unless your own treating specialist changes it.
Nothing is scheduled or billed during this stage — it is a review and conversation, not a commitment.
12Our Approach to Systemic Lupus Care
For lupus patients — particularly those with disease that hasn't responded well to standard therapy — we present MSC infusion as a genuinely researched, investigational option, grounded in real Phase I/II trial data, while being clear that it is not a cure and should complement ongoing rheumatology care.
13Cost and How Stem Cell Therapy Compares for Systemic Lupus
Cost varies by patient based on medical history, the number of sessions recommended, and diagnostic requirements. Because stem cell therapy is offered outside standard insurance-covered pathways in most countries, patients are encouraged to request a personalized quote and to independently verify what is and is not included (consultation, cell processing, hospital stay, and follow-up).
14Why Systemic Lupus Patients Consider Treatment in India
Considerations for patients weighing this option:
- Real Trial Infrastructure: Lupus is one of the better-studied autoimmune conditions for MSC therapy, with academic-center Phase I/II trials completed.
- Immunomodulatory Rationale: MSCs' ability to calm rather than broadly suppress the immune system is mechanistically relevant to lupus.
- Still Investigational: Results are mixed across trials, and this is not yet a standard or guaranteed treatment.
- Best for Refractory Disease: Most evidence applies to patients who haven't responded well to conventional therapy, not as a first-line option.
15Quality Control in Cell Processing for Systemic Lupus Therapy
Stem Cell Care India applies standard laboratory safety and screening protocols to cell processing, including infectious disease screening, microbial contamination testing, and endotoxin testing, before any cell product is cleared for use. Patients are encouraged to ask for documentation of these safety checks and of the qualifications of the treating medical team.
16What Systemic Lupus Patients May Notice After Treatment
Brain injuries can range from mild to severe, and outcomes after any treatment tend to reflect that range. The idea behind exploring stem cell approaches in this context is to support the brain's own capacity to begin repairing itself, in the hope of helping patients regain functions that might otherwise remain out of reach — though this is discussed as a possible supportive step, not a guaranteed one. Reported experiences following stem cell therapy for systemic lupus vary from patient to patient and depend on factors such as age and injury severity. Changes some patients have reported include:
- Signs of repair in previously damaged brain tissue on follow-up assessment
- Reduced swelling or inflammation
- Changes in memory or thinking skills
- Changes in movement, balance, or coordination
- Changes in speech and communication
- General alertness and activity levels
- Support for the growth of new, healthy cells
- A generally faster pace of the body's own natural healing
Stem cell therapy is not positioned as a permanent cure for systemic lupus, and any benefit may take time to appear or may not appear at all. It is generally discussed as a complement to, not a replacement for, other supportive therapies.
17Quality Certification for Systemic Lupus Therapy
A quality certificate is intended to document that the cell-processing steps used for a given batch were carried out under stated laboratory protocols and that the resulting cells met the facility's internal quality checks. Stem Cell Care India states that its cell-processing procedures are documented in this way, that patients are not charged extra for this documentation, and that equipment used is checked ahead of each procedure.
The clinic describes this certification as reflecting ethical practice, with patient safety, informed consent, and clear information treated as priorities, alongside ongoing internal checks on quality and procedure. This documentation reflects internal laboratory quality assurance rather than a government approval of the therapy itself for curing Systemic Lupus, and a supporting team of medical staff is described as being available throughout the process.
18Systemic Lupus Follow-Up Care
Patients pursuing this option are advised to maintain close, ongoing follow-up with their treating rheumatologist, including routine lupus activity scoring and organ function monitoring (especially kidney function), regardless of any experimental therapy pursued.
19Supportive Therapies Sometimes Used Alongside Systemic Lupus Treatment
Stem cell therapy is generally discussed as one part of a broader recovery plan rather than a stand-alone treatment. Supportive therapies sometimes used alongside it for systemic lupus include:
- Psychological support: To help address mood changes, anxiety, or emotional stress that can follow a systemic lupus.
- Speech therapy: For patients experiencing difficulty speaking, swallowing, or understanding language.
- Physiotherapy: To help rebuild movement, balance, and muscle strength.
- Hyperbaric oxygen therapy: Delivering oxygen at increased pressure, which is being explored as a supportive measure for tissue recovery.
- Acupuncture: Used by some patients as a complementary approach alongside conventional care.
- Rehabilitation therapy: Structured practice of daily tasks to support functional recovery.
- Occupational therapy: Support for relearning tasks such as dressing, eating, and writing.
- Nutrition therapy: Dietary guidance intended to support general recovery.
- Nerve Growth Factor (NGF) treatment: Supports the survival and growth of nerve cells; when discussed alongside stem cell therapy, it is explored for its potential to support nerve repair and overall brain recovery.
Any combination of these should be planned together with the treating medical team rather than pursued independently.
20Why Some International Systemic Lupus Patients Consider India
Patients travel to India from the USA, UK, Europe, the Gulf region, and elsewhere for a range of medical treatments, often citing cost and access to specialized centers as key factors.
What Brings International Patients to Choose India for Medical Treatments?
- Specialized Centers: Hospitals maintain dedicated regenerative medicine departments with laboratory facilities.
- Medical Visa Assistance: Support with medical visas and required travel documentation.
- Airport Pickup and Drop: Airport transfer services on arrival and departure.
- Multilingual Support: Interpreters and translators to support non-English-speaking patients.
- Accommodation Support: In-house stays, guest houses, or hotel partnerships for comfortable lodging.
- Cost: Generally lower than equivalent private care in the US, UK, or Western Europe, though patients should request itemized quotes.
21Selected Systemic Lupus Research & Publications
Verified, publicly available research relevant to this topic includes:
- A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus (MiSLE). ClinicalTrials.gov NCT02633163. Medical University of South Carolina.
- A Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus. ClinicalTrials.gov NCT03171194. Medical University of South Carolina.
- Efficacy and Safety of Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Multiple Sclerosis, and Ankylosing Spondylitis): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Readers should treat any additional named studies, institutions, or statistics cited elsewhere on this topic with caution unless they can be verified through PubMed, ClinicalTrials.gov, or the original journal.
22Conclusion: Stem Cell Therapy for Systemic Lupus
Lupus is a complex, unpredictable autoimmune disease, and living with refractory disease that doesn't respond to standard treatment can be exhausting. Mesenchymal stem cell therapy is a genuine, actively studied research direction for this group of patients, with real Phase I/II trial data behind it — more than many conditions covered on this site.
That said, results across trials are mixed, and this remains an investigational approach best pursued alongside, not instead of, ongoing rheumatology care and honest expectations about what the evidence currently shows.
Treatment Disclaimer: We provide consultation, case evaluation, and patient support services in the field of regenerative medicine. This page is for informational purposes and does not constitute medical advice or a guarantee of outcome.
Not sure if this applies to your case?
Share your diagnosis and reports, and our medical team will get back to you with a free, doctor-reviewed opinion on Systemic Lupus — no obligation.
- Reviewed by our in-house medical team
- Doctor-reviewed reply within 24–48 hours
- No cost and no obligation to proceed
- Your information is kept confidential
Get Your Free Evaluation
Frequently Asked Questions
No. It remains investigational, studied mainly in Phase I/II academic trials for patients with refractory disease. It is not a standard, first-line lupus treatment.
Published Phase I/II trials have generally reported that MSC infusion is safe and tolerable, with some patients showing reduced disease activity, though outcomes are mixed and further confirmatory research is ongoing.
No. Any change to your treatment plan should be made with your treating rheumatologist; MSC therapy in published trials has been used alongside, not instead of, standard care.
Trials have generally reported a favorable safety profile, but as with any infusion-based therapy, there are risks, and results should not be assumed to generalize to every patient.
Medically reviewed by the Stem Cell Care India clinical team. Last reviewed 2 September 2026. Written by Nishat Arfin · Scientific review by Tabish Iqbal · Medically approved by the Stem Cell Care India Medical Team.
Investigational-status disclaimer. This content is for informational and educational purposes only. Stem cell therapy for Systemic Lupus is considered investigational under current medical guidelines in India and is not FDA-approved. No guarantees or claims of cure are made. Results vary from patient to patient. Please consult a qualified healthcare professional before making any medical decisions.